The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism

Drug Metabolism Reviews

Volumn 33, Issue 3-4, 2001, Pages 273-297

  Fisher, Michael B ^a   Paine, Mary F ^b   Strelevitz, Timothy J ^a   Wrighton, Steven A ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALAMETHICIN; BILIRUBIN; BUPRENORPHINE; CYTOCHROME P450; ESTRADIOL; ETHINYLESTRADIOL; GENE PRODUCT; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; ISOPROTEIN; LORAZEPAM; MORPHINE; PARACETAMOL; UNCLASSIFIED DRUG;

ALLELISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME SPECIFICITY; FIRST PASS EFFECT; GASTROINTESTINAL TRACT FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDIVIDUALITY; INTESTINE EPITHELIUM; LIVER CLEARANCE; LIVER METABOLISM; PROTEIN EXPRESSION; REVIEW; TISSUE DISTRIBUTION;

GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 0035209568     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120000653     Document Type: Review

References (80)

1. Eddershaw, P.J.; Beresford, A.P.; Bayliss, M.K. ADME/PK as Part of a Rational Approach to Drug Discovery. Drug Discovery Today 2000, 5, 409-414.
2. Riley, R.J. The Potential Pharmacological and Toxicological Impact of P450 Screening. Curr. Opin. Drug Discovery Dev. 2001, 4, 45-54.
3. Obach, R.S. The Prediction of Human Clearance from Hepatic Microsomal Metabolism Data. Curr. Opin Drug Discovery Dev. 2001, 4, 36-44.
4. Fisher, M.B.; Campanale, K.; Ackermann, B.L.; VandenBranden, M.; Wrighton, S.A. In Vitro Glucuronidation Using Human Liver Microsomes and the Pore-Forming Peptide Alamethicin. Drug Metab. Dispos. 2000, 28, 560-566.
5. Meech, R.; Mackenzie, P.I. Structure and Function of Uridinediphosphate Glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 1997, 24, 907-915.
6. Miners, J.O.; Mackenzie, P.I. Drug Glucuronidation in Humans. Pharmacol Ther. 1991, 51, 347-369.
7. Radominska-Pandya, A.; Czernik, P.J.; Little, J.M.; Battaglia, E.; Mackenzie, P.I. Structural and Functional Studies of UDP-Glucuronosyltransferases. Drug Metab. Rev. 1999, 31, 817-899.
8. Mackenzie, P.I.; Owens, I.S.; Burchell, B.; Bock, K.W.; Bairoch, A.; Belanger, A.; Fournel-Gigleux, S.; Green, M.; Hum, D.W.; Iyanagi, T.; Lancet, D.; Louisot, P.; Magdalou, J.; Chowdhury, J.R.; Ritter, J.K.; Schachter, H.; Tephly, T.R.; Tipton, K.F.; Nebert, D.W. The UDP-Glycosyltransferase Gene Superfamily: Recommended Nomenclature Update Based on Evolutionary Divergence. Pharmacogenetics 1997, 7, 255-269.
9. Tukey, R.H.; Strassburg, C.P. Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581-616.
10. Ritter, J.K. Roles of Glucuronidation and UDP-Glucuronosyltransferases in Xenobiotic Bioactivation Reactions. Chem. Biol. Interact. 2000, 129, 171-193.
11. Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications; 3rd Ed; Williams and Wilkins: Media, PA, 1995.
12. Hanninen, O.; Alanen, K. The Competitive Inhibition of p-Nitrophenyl-β-D-Glucopyranosiduronic Acid Synthesis by Aliphatic Alcohols In Vitro. Biochem. Pharmacol. 1966, 15, 1465-1467.
13. Yokota, H.; Ando, F.; Iwano, H.; Yuasa, A. Inhibitory Effects of Uridine Diphosphate on UDP-Glucuronosyltransferase. Life Sci. 1998, 63, 1693-1699.
14. Bechinger, B. Structure and Functions of Channel-Forming Peptides: Magainins, Cecropins, Melittin, and Alamethicin. J. Membr. Biol. 1997, 156, 197-211.
15. Wang, T.-F.; Guidotti, G. Golgi Localization and Functional Expression of Human Uridine Diphosphatase. J. Biol. Chem. 1998, 273, 11392-11399.
16. Puskas, F.; Braun, L.; Csala, M.; Kardon, T.; Marcolongo, P.; Benedetti, A.; Mandl, J.; Banhegyi, G. Gulonolactone Oxidase Activity-Dependent Intravesicular Glutathione Oxidation in Rat Liver Microsomes. FEBS Lett. 1998, 430, 293-296.
17. Banhegyi, G.; Csala, M.; Mand, J.; Burchell, A.; Burchell, B.; Marcolongo, P.; Fulceri, R.; Benedetti, A. Fatty Acyl-CoA Esters and the Permeability of Rat Liver Microsomal Vesicles. Biochem. J. 1996, 320, 343-344.
18. Banhegyi, G.; Marcolongo, P.; Fulceri, R.; Hinds, C.; Burchell, A.; Benedetti, A. Demonstration of a Metabolically Active Glucose-6-Phosphate Pool in the Lumen of Liver Microsomal Vesicles. J. Biol. Chem. 1997, 272, 13584-13590.
19. Vanstapel, F.; Blanckaert, N. Topology and Regulation of Bilirubin UDP-Glucuronyltransferase in Sealed Native Microsomes from Rat Liver. Arch. Biochem. Biophys. 1988, 263, 216-225.
20. Banhegyi, G.; Bellomo, G.; Fulceri, R.; Mandl, J.; Benedetti, A. Intralumenal Calcium of the Liver Endoplasmic Reticulum Stimulates the Glucuronidation of p-Nitrophenol. Biochem. J. 1993, 292, 99-104.
21. Little, J.M.; Lehman, P.A.; Nowell, S.; Samokyszyn, V.; Radominska, A. Glucuronidation of all-trans-Retinoic Acid and 5,6-Epoxy-all-trans-Retinoic Acid. Drug Metab. Dispos. 1997, 25, 5-11.
22. Fulceri, R.; Banhegyi, G.; Gamberucci, A.; Giunti, R.; Mandl, J.; Benedetti, A. Evidence for the Intraluminal Positioning of p-Nitrophenol UDP-Glucuronosyltransferase Activity in Rat Liver Microsomal Vesicles. Arch. Biochem. Biophys. 1994, 309, 43-46.
23. Zakim, D.; Goldenberg, J.; Vessey, D. A. Effects of Metals on the Properties of Hepatic Microsomal Uridine Diphosphate Glucuronyltransferase. Biochemistry 1973, 12, 4068-4074.
24. Yamamura, N.; Imura-Miyoshi, K.; Naganuma, H. Panipenum, a Carbapenem Antibiotic, Increases the Level of Hepatic UDP-Glucuronic Acid in Rats. Drug Metab. Dispos. 2000, 28, 1484-1486.
25. Sugiyama, T.; Goldman, W.F. Measurement of SR Free Ca and Mg in Permeabilized Smooth Muscle Cells with Use of Furaptra. Am. J. Physiol. 1995, 269, C698-C705.
26. Kim, J.H.; Johannes, L.; Goud, B.; Antony, C.; Lingwood, C.A.; Daneman, R.; Grinstein, S. Noninvasive Measurement of the pH of the Endoplasmic Reticulum at Rest and During Calcium Release. Proc. Natl Acad. Sci. USA 1998, 95, 2997-3002.
27. Yu, W.; Enriquez, P. LC/MS/MS Analysis of Drug Conjugates: A Potential Error Source for Quantitation also Provides a Means for Assessing Drug Absorption. ISSX Proc. 1999, 15, 234.
28. Coffman, B.L.; Rios, G.R.; King, C.D.; Tephly, T.R. Human UGT2B7 Catalyzes Morphine Glucuronidation. Drug Metab. Dispos. 1997, 25, 1-4.
29. Senafi, S.B.; Clarke, D.J.; Burchell, B. Investigation of the Substrate Specificity of a Cloned Expressed Human Bilirubin UDP-Glucuronosyltransferase: UDP Sugar Specificity and Involvement in Steroid and Xenobiotic Glucuronidation. Biochem. J. 1994, 303, 233-240.
30. Breyer-Pfaff, U.; Mey, U.; Green, M.D.; Tephly, T.R. Comparative N-Glucuronidation Kinetics of Ketotifen and Amitryptyline by Expressed Human UDP-Glucuronosyltransferases and Liver Microsomes. Drug Metab. Dispos. 2000, 28, 869-872.
31. Strassburg, C.P.; Kneip, S.; Topp, J.; Obermayer-Straub, P.; Barut, A.; Tukey, R.H.; Manns, M.P. Polymorphic Gene Regulation and Interindividual Variation of UDP-Glucuronosyltransferase Activity in Human Small Intestine. J. Biol. Chem. 2000, 275, 36164-36171.
32. McGurk, K.A.; Brierley, C.H.; Burchell, B. Drug Glucuronidation by Human Renal UDP-Glucuronosyltransferases. Biochem. Pharmacol. 1998, 55, 1005-1012.
33. Thummel, K.E.; Kunze, K.L.; Shen, D.D. Enzyme-Catalyzed Processes of First-Pass Hepatic and Intestinal Drug Extraction. Adv. Drug Deliv. Rev. 1997, 27, 99-127.
34. Fisher, M.B.; VandenBranden, M.; Findlay, K.; Burchell, B.; Thummel, K.E.; Hall, S.D.; Wrighton, S.A. Tissue Distribution and Interindividual Variation in Human UDP-Glucuronosyltransferase Activity: Relationship Between UGT1A1 Promoter Genotype and Variability in a Liver Bank. Pharmacogenetics 2000, 10, 727-739.
35. Czernick, P.J.; Little, J.M.; Barone, G.W.; Raufman, J.-P.; Radominska-Pandya, A. Glucuronidation of Estrogens and Retinoic Acid and Expression of UDP-Glucuronosyltransferase 2B7 in Human Intestinal Mucosa. Drug Metab. Dispos. 2000, 28, 1210-1216.
36. Paine, M.F.; Fisher, M.B. Immunochemical Identification of UGT Isoforms in Human Small Bowel and in Caco-2 Cell Monolayers. Biochem. Biophys. Res. Commun. 2000, 273, 1053-1057.
37. Radominska-Pandya, A.; Little, J.M.; Pandya, J.T.; Tephly, T.R.; King, C.D.; Barone, G.W.; Raufman, J.-P. UDP-Glucuronosyltransferases in Human Intestinal Mucosa. Biochim. Biophys. Acta 1998, 1394, 199-208.
38. Veroli, P.; O'Kelly, B.; Bertrand, F.; Trouvin, J.H.; Farinotti, R.; Ecoffey, C. Extrahepatic Metabolism of Propofol in Man During the Anhepatic Phase of Orthotopic Liver Transplantation. Br. J. Anaesth. 1992, 68, 183-186.
39. Raoof, A.A.; van Obbergh, L.J.; de Ville de Goyet, J.; Verbeeck, R.K. Extrahepatic Glucuronidation of Propofol in Man: Possible Contribution of Gut Wall and Kidney. Eur. J. Clin. Pharmacol. 1996, 50, 91-96.
40. Cheng, Z.; Radominska-Pandya, A.; Tephly, T.R. Studies on the Substrate Specificity of Human Intestinal UDP-Glucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos. 1999, 27, 1165-1170.
41. Ethell, B.T.; Beaumont, K.; Rance, D.J.; Burchell, B. Use of Cloned and Expressed Human UDP-Glucuronosyltransferases for the Assessment of Human Drug Conjugation and Identification of Potential Drug Interactions. Drug Metab. Dispos. 2001, 29, 48-53.
42. 3-Modified Caco-2 Cell Monolayers. J. Pharm. Exp. Ther. 1999, 289, 1134-1142.
43. Paine, M.F.; Schmedlin-Ren, P.; Watkins, P.B.; Drug Metab. Dispos. 1999, 27, 360-364.
44. Ritter, J.K.; Kessler, F.K.; Thompson, M.T.; Grove, A.D.; Auyeung, D.J.; Fisher, R.A. Expression and Inducibility of the Human Bilirubin UDP-Glucuronosyl-transferase UGT1A1 in Liver and Cultured Primary Hepatocytes: Evidence for Both Genetic and Environmental Influences. Hepatology 1999, 30, 476-484.
45. Yue, Q.; Odar-Cederlof, I.; Svensson, J.-O.; Sawe, J. Glucuronidation of Morphine in Human Kidney. Pharmacol. Toxicol. 1988, 63, 337-341.
46. Yue, Q.; von Bahr, C.; Odar-Cederlof, I.; Sawe, J. Glucuronidation of Codeine and Morphine in Human Liver and Kidney Microsomes: Effect of Inhibitors. Pharmacol. Toxicol. 1990, 66, 221-226.
47. Brunelle, F.M.; Verbeeck, R.K. Glucuronidation of Diflunisal in Liver and Kidney Microsomes of Rat and Man. Xenobiotica 1996, 26, 123-131.
48. Vietri, M.; Pietrabissa, A.; Mosca, F.; Pacifici, G.M. Mycophenolic Acid Glucuronidation and Its Inhibition by Non-steroidal Anti-Inflammatory Drugs in Liver and Kidney. Eur. J. Clin. Pharmacol. 2000, 56, 659-664.
49. Little, J.M.; Lester, R.; Kuipers, F.; Vonk, R.; Mackenzie, P.I.; Drake, R.R.; Frame, L.; Radominska-Pandya, A. Variability of Human Hepatic UDP-Glucuronosyltransferase Activity. Acta Biochim. Pol. 1999, 46, 351-363.
50. Lacarelle, B.; Rajaonarison, J.F.; Gauthier, T.; Placidi, M.; Catalin, J.; Rahmani, R. Use of a Human Liver Bank in Drug Glucuronidation Studies. Toxicol. In Vitro 1991, 5, 559-562.
51. Burchell, B.; Soars, M.; Monaghan, G.; Cassidy, A.; Smith, D.; Ethell, B. Drug-Mediated Toxicity Caused by Genetic Deficiency of UDP-Glucuronosyltransferases. Toxicol. Lett. 2000, 112-113, 333-340.
52. Mackenzie, P.I.; Miners, J.O.; McKinnon, R.A. Polymorphisms in UDP-Glucuronosyltransferase Genes: Functional Consequences and Clinical Relevance. Clin. Chem. Lab. Med. 2000, 38, 889-892.
53. Beutler, E.; Gelbart, T.; Demina, A. Racial Variability in the UDP-Glucuronosyltransferase 1 (UGT1A1) Promoter: a Balanced Polymorphism for Regulation of Bilirubin Metabolism? Proc. Natl Acad. Sci. USA 1998, 95, 8170-8174.
54. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R.; Burchell, B. Genetic Variation in Bilirubin UDP-Glucuronosyltransferase Gene Promoter and Gilbert's Syndrome. Lancet 1996, 347, 578-581.
55. Burchell, B.; Hume, R. Molecular Genetic Basis of Gilbert's Syndrome. J. Gastroenterol. Hepatol. 1999, 14, 960-966.
56. Trapnell, C.B.; Klecker, R.W.; Jamis-Dow, C.; Collins, J.M. Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid. Antimicrob. Agents Chemother. 1998, 42, 1592-1596.
57. Galijatovic, A.; Walle, U.K.; Walle, T. Induction of UDP-Glucuronosyltransferase by the Flavonoids Chrysin and Quercetin in Caco-2 Cells. Pharm. Res. 2000, 17, 21-26.
58. Munzel, P.A.; Schmohl, S.; Heel, H.; Kalberer, K.; Bock-Hennig, B.S.; Bock, K.W. Induction of Human UDP-Glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-Butylhydroquinone and 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Caco-2 cells. Drug Metab. Dispos. 1999, 27, 569-573.
59. Brierley, C.H.; Senafi, S.B.; Clarke, D.; Hsu, M.-H.; Johnson, E.F.; Burchell, B. Regulation of the Human Bilirubin UDP-Glucuronosyltransferase Gene. Adv. Enzyme Regul. 1996, 36, 85-97.
60. Belanger, A.; Hum, D.W.; Beaulieu, M.; Levesque, E.; Guillemette, C.; Tchernof, A.; Belanger, G.; Turgeon, D.; Dubois, S. Characterization and Regulation of UDP-Glucuronosyltransferases in Steroid Target Tissues. J. Steroid Biochem. 1998, 65, 301-310.
61. Levesque, E.; Beaulieu, M.; Guillemette, C.; Hum, D.W.; Belanger, A. Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line. Endocrinology 1998, 139, 2375-2381.
62. de Wildt, S.N.; Kearns, G.L.; Leeder, J.S.; van den Anker, J.N. Glucuronidation in Humans: Pharmacogenetic and Developmental Aspects. Clin. Pharmacokinet. 1999, 36, 439-452.
63. Bouska, J.J.; Bell, R.L.; Goodfellow, C.L.; Stewart, A.O.; Brooks, C.D.W.; Carter, G.W. Improving the In Vivo Duration of 5-Lipoxygenase Inhibitors. Drug Metab. Dispos. 1997, 25, 1032-1038.
64. Houston, J.B.; Kenworthy, K.E. In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model. Drug Metab. Dispos. 2000, 28, 246-254.
65. Reisine, T.; Pasternak, G. Opioid Analgesics and Antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics; Hardman, J.G., Gilman, A.G., Limbird, L.E. Eds.; Chap. 23; McGraw-Hill: New York, 1996, 521-556.
66. Mistry, M.; Houston, J.B. Glucuronidation In Vitro and In Vivo: Comparison of Intestinal and Hepatic Conjugation of Morphine, Naloxone, and Buprenorphine. Drug Metab. Dispos. 1987, 15, 710-717.
67. Bruni, S.; Chang, T.M.S. Kinetic Studies of Hepatocytes UDP-Glucuronosyltransferase: Evidence of an Allosteric Enzyme. Art. Cells Blood Subs. Immob. Biotechnol. 1999, 27, 343-356.
68. Beckmann, J.D.; Henry, T.; Ulphani, J.; Lee, P. Cooperative Ligand Binding by Bovine Phenol Sulfotransferase. Chem.-Biol. Interact. 1998, 109, 93-105.
69. Ekins, S.; Ring, B.J.; Binkley, S.N.; Hall, S.D.; Wrighton, S.A. Autoactivation and Activation of the Cytochrome P450s. Int. J. Clin. Pharmacol. Ther. 1998, 36, 642-651.
70. Korzekwa, K.R.; Krishnamachary, N.; Shou, M.; Ogai, A.; Parise, R.A.; Rettie, A.E.; Gonzalez, F.J.; Tracy, T.S. Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence that Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites. Biochemistry 1998, 37, 4137-4147.
71. 2+. Drug Metab. Dispos. 2000, 28, 1198-1201.
72. Jakoby, W.B.; Ziegler, D.M. The Enzymes of Detoxication. J. Biol. Chem. 1990, 265, 20715-20718.
73. Shou, M.; Dai, R.; Cui, D.; Korzekwa, K.R.; Baillie, T.A.; Rushmore, T.H. A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4. J. Biol. Chem. 2001, 276, 2256-2262.
74. Weiss, J.N. The Hill Equation Revisited: Uses and Misuses. FASEB J. 1997, 11, 835-841.
75. Vree, T.B.; van Dongen, R.T.M.; Koopman-Kimenai, P.M. Codeine Analgesia Is Due to Codeine-6-Glucuronide, Not Morphine. IJCP 2000, 54, 395-398.
76. Wrighton, S.A.; Schuetz, E.G.; Thummel, K.E.; Shen, D.D.; Korzekwa, K.R.; Watkins, P.B. The Human CYP3A Subfamily: Practical Considerations. Drug Metab. Rev. 2000, 32, 339-361.
77. Paine, M.F.; Khalighi, M.; Fisher, J.M.; Shen, D.D.; Kunze, K.L.; Marsh, C.L.; Perkins, J.D.; Thummel, K.E. Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism. J. Pharm. Exp. Ther. 1997, 283, 1552-1562.
78. Iyer, L.; Hall, D.; Das, S.; Mortell, M.A.; Ramirez, J.; Kim, S.; Di Rienzo, A.; Ratain, M.J. Phenotype-Genotype Correlation of In Vitro SN-38 (Active Metabolite of Irinotecan) and Bilirubin Glucuronidation in Human Liver Tissue with UGT1A1 Promoter Polymorphism. Clin. Pharmacol. Ther. 1999, 65, 576-582.
79. Lin, J.H.; Lu, A.Y.H. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development. Pharmacol. Rev. 1997, 49, 403-449.
80. Guengerich, F.P. Pharmacogenomics of Cytochrome P450 and Other Enzymes Involved in Biotransformation of Xenobiotics. Drug Dev. Res. 2000, 49, 4-16.